中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
13期
64-65
,共2页
恶性肿瘤%化疗%血小板减少%重组人白介素-11衍生物
噁性腫瘤%化療%血小闆減少%重組人白介素-11衍生物
악성종류%화료%혈소판감소%중조인백개소-11연생물
Malignant tumor%Chemotherapy%Thrombocytopenia%Recombinant human interleukin -11 derivatives
目的:探讨重组人白介素-11(rhIL-11)衍生物在治疗恶性肿瘤患者化疗后血小板减少的临床应用效果。方法:2012年1月-2014年1月收治恶性肿瘤患者40例,采用自身对照试验,分为2个周期,第1个治疗周期化疗后不加用rhIL-11,第2个周期化疗后24~48 h内加用rhIL-11治疗,比较两组血小板减少情况。结果:40例患者在第2个周期时的血小板计数最低值明显高于第1个周期(P<0.05),血小板计数≤50×109/L的持续时间明显小于第1个周期(P<0.05),血小板恢复至正常值的时间明显短于第1个周期(P<0.05),输注血小板的发生率明显小于第1个周期(P<0.05),所有患者第2个周期无出血发生,且不良反应轻微。结论:rhIL-11衍生物在预防恶性肿瘤患者化疗后血小板减少中的作用显著,且不良反应轻微,值得推广应用。
目的:探討重組人白介素-11(rhIL-11)衍生物在治療噁性腫瘤患者化療後血小闆減少的臨床應用效果。方法:2012年1月-2014年1月收治噁性腫瘤患者40例,採用自身對照試驗,分為2箇週期,第1箇治療週期化療後不加用rhIL-11,第2箇週期化療後24~48 h內加用rhIL-11治療,比較兩組血小闆減少情況。結果:40例患者在第2箇週期時的血小闆計數最低值明顯高于第1箇週期(P<0.05),血小闆計數≤50×109/L的持續時間明顯小于第1箇週期(P<0.05),血小闆恢複至正常值的時間明顯短于第1箇週期(P<0.05),輸註血小闆的髮生率明顯小于第1箇週期(P<0.05),所有患者第2箇週期無齣血髮生,且不良反應輕微。結論:rhIL-11衍生物在預防噁性腫瘤患者化療後血小闆減少中的作用顯著,且不良反應輕微,值得推廣應用。
목적:탐토중조인백개소-11(rhIL-11)연생물재치료악성종류환자화료후혈소판감소적림상응용효과。방법:2012년1월-2014년1월수치악성종류환자40례,채용자신대조시험,분위2개주기,제1개치료주기화료후불가용rhIL-11,제2개주기화료후24~48 h내가용rhIL-11치료,비교량조혈소판감소정황。결과:40례환자재제2개주기시적혈소판계수최저치명현고우제1개주기(P<0.05),혈소판계수≤50×109/L적지속시간명현소우제1개주기(P<0.05),혈소판회복지정상치적시간명현단우제1개주기(P<0.05),수주혈소판적발생솔명현소우제1개주기(P<0.05),소유환자제2개주기무출혈발생,차불량반응경미。결론:rhIL-11연생물재예방악성종류환자화료후혈소판감소중적작용현저,차불량반응경미,치득추엄응용。
Objective:To investigate the effect of thrombocytopenia in patients with malignant tumor who were treated with recombinant human interleukin-11 derivatives.Methods:40 patients with malignant tumor were selected from January 2012 to January 2014.With a self control,this study divided into 2 periods,in the first treatment cycles,did not given rhIL-11 after chemotherapy,while in the second cycles,patients were given rhIL-11 within 24~48 h after chemotherapy,then we compared thrombocytopenic conditions in two groups.Results:In those 40 patients the lowest value of platelet count in the second cycle was significantly higher than that in the first period(P<0.05);the duration of platelet count less than 50 × 109/L was significantly shorter than the first cycles(P<0.05),and the time of platelet recovery to normal value also was obviously shorter than the first cycles(P<0.05);the incidence of platelet transfusion was significantly less than the first cycles(P<0.05);none of the patients occurred hemorrhage in second cycles,and the adverse reaction was mild.Conclusion:RhIL-11 derivatives used in patients with malignant tumor has significantly effect on prevention of thrombocytopenia after chemotherapy,and the adverse reactions is mild, so it is worthy of popularization and application.